JPY 2065.0
(0.05%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.29 Billion JPY | 11.26% |
2022 | 1.19 Billion JPY | 34.19% |
2021 | 885 Million JPY | 9.51% |
2020 | 814 Million JPY | -31.35% |
2019 | 1.24 Billion JPY | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 461 Million JPY | 368.02% |
2023 Q3 | 348 Million JPY | 34.36% |
2023 Q2 | 259 Million JPY | -33.07% |
2023 Q4 | -172 Million JPY | -149.43% |
2023 FY | - JPY | 11.26% |
2023 Q1 | 387 Million JPY | 945.95% |
2022 Q3 | -1 Million JPY | -100.34% |
2022 FY | - JPY | 34.19% |
2022 Q4 | 37 Million JPY | 3800.0% |
2022 Q2 | 290 Million JPY | 0.0% |
2021 FY | - JPY | 9.51% |
2020 FY | - JPY | -31.35% |
2019 FY | - JPY | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 78.525% |
Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.852% |
Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 100.46% |
Shionogi & Co., Ltd. | 186.7 Billion JPY | 99.307% |
Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -126.456% |
Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 96.437% |
Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 89.46% |
Eisai Co., Ltd. | 103.1 Billion JPY | 98.746% |
Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 92.95% |
Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 85.59% |
Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 64.768% |
Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 7.84% |
Tsumura & Co. | 30.77 Billion JPY | 95.798% |
Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 93.093% |
Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 75.47% |
Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 96.361% |
Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 81.212% |
Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 92.621% |
KYORIN Holdings, Inc. | 10.29 Billion JPY | 87.442% |
Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 134.48% |
Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 82.881% |
SymBio Pharmaceuticals Limited | -714 Million JPY | 281.092% |
MedRx Co., Ltd | -884.51 Million JPY | 246.182% |
Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 76.645% |
Solasia Pharma K.K. | -635 Million JPY | 303.622% |
Modalis Therapeutics Corporation | -2.37 Billion JPY | 154.467% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 85.889% |
Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 96.493% |
Cyfuse Biomedical K.K. | -538.28 Million JPY | 340.206% |
Toho Holdings Co., Ltd. | 25.84 Billion JPY | 94.997% |
Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 74.655% |